联合应用埃索美拉唑、铝碳酸镁和莫沙比利治疗难治性胃食管反流病  

Efficacy of esomeprazole combined with hydrotalcite and mosapride in treatment of refractory gastroesophageal reflux disease

作　　者：王战波[1] 陈玲玲[1] 游旭东[1] 

机构地区：[1]河南平顶山煤业集团总医院消化内科,河南省平顶山市467000

出　　处：《世界华人消化杂志》2007年第8期901-904,共4页World Chinese Journal of Digestology

摘　　要：目的:探讨联合应用埃索美拉唑、铝碳酸镁和莫沙比利治疗难治性胃食管反流病(r-GERD)的临床疗效．方法:101例rGERD患者随机为A(n=36),B (n=34)和C组(n=31),分别采用埃索美拉唑+铝碳酸镁+莫沙比利、埃索美拉唑+莫沙比利及铝碳酸镁+莫沙比利治疗．4及8 wk后评价临床症状,8 wk后评价内镜下有效率．结果:治疗4 wk后,A,B和C组临床症状总改善率分别为88．9％,79．4％和61．3％,A组与B,C两组相比差异显著(X2=7．3531,P<0．05)．治疗8 wk后,A,B和C组临床症状总改善率分别为97．2％,88．2％和7 1．0％,内镜下有效率分别为94．4％,85．3％和67．7％,A组临床症状总改善率和内镜下有效率与B,C组相比存在显著性差异(X2=9．6079,P<0．01;);X2=8．6496,P<0．05)．结论:埃索美拉唑联合铝碳酸镁和莫沙比利治疗rGERD有很高的临床疗效．AIM： To evaluate the effect of esomeprazole combined with hydrotalcite and mosapride on refractory gastroesophageal reflux disease （rGERD）. METHODS： A total of 101 rGERD patients were randomly divided into groups A （n = 36）, B B （n = 34） and C （n = 31）, treated with esomeprazole plus hydrotalcite plus mosapride, esomeprazole plus mosaride, and hydrotacite plus mosapride, respectively. The clinical outcomes were observed and analyzed after 4 and 8 weeks of treatment. Endoscopy was performed to evaluate the effective rate in the three groups. RESULTS： After 4 weeks of treatment, the total improvement rate was significantly higher in group A （88.9%） than that in group B （79.4%） and C （61.3%） （χ^2= 7.3531, P 〈 0.05）. Eight weeks after treatment, the total improvement rates were 97.2%, 88.2% and 71.0% in group A, B and C, ,and the effective rates detected by endoscopy were 94.4%, 85.3% and 67.7%, respectively. The total improvement rate （χ^2= 9.6039, P 〈 0.01） and effective rate （χ^2 = 8.6496, P 〈 0.05） were markedly higher in group A than those in B and C group. CONCLUSION： Esomeprazole combined with hydrotalcite and mosapride may be highly effective in the treatment of rGERD.

关 键 词：胃食管反流病 埃索美拉唑 铝碳酸镁 莫沙比利 

分 类 号：R571[医药卫生—消化系统]